Safety and effectiveness of tofogliflozin in Japanese people with type 2 diabetes: A multicenter prospective observational study in routine clinical practice.

Yuichiro Yamada Daisuke YabeKenichiro ShideAtsushi SuzukiYasuo TerauchiYasunori SatoNobuyuki ShiharaYutaka Seino

Published in: Journal of diabetes investigation (2024)

Tofogliflozin was associated with only mild or moderate ADRs characteristic of SGLT2 inhibitors, with no unpredictable, new, serious, or high-incidence adverse events or ADRs. This independent study confirmed the safety and effectiveness of tofogliflozin in adult type 2 diabetes patients.

Keyphrases

clinical practice
type diabetes
end stage renal disease
randomized controlled trial
systematic review
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
cardiovascular disease
risk factors
clinical trial
stress induced
patient reported outcomes
adipose tissue
skeletal muscle